Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial-Reference-Cited by-同舟云学术

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Published:2010-10 Issue:9747 Volume:376 Page:1155-1163
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Rustin Gordon JS,van der Burg Maria EL,Griffin Clare L,Guthrie David,Lamont Alan,Jayson Gordon C,Kristensen Gunnar,Mediola César,Coens Corneel,Qian Wendi,Parmar Mahesh KB,Swart Ann Marie

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)

2. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial;Falk;BMJ,2002

3. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial;Ardeshna;Lancet,2003

4. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial;J Clin Oncol,1992

5. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial;O'Brien;Ann Oncol,2006

Cited by 474 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology of Gynaecological Cancer: Ovarian, Endometrial and Cervical;International Encyclopedia of Public Health;2025

2. Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3;Gynecologic Oncology;2024-11

3. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

4. Assessing the Evidence for Circulating Tumor HPV DNA in Patients With Oropharyngeal Cancer;JAMA Oncology;2024-08-01

5. Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer;Scientific Reports;2024-07-29